行情

BLPH

BLPH

柏勒罗丰治疗
NASDAQ

实时行情|Nasdaq Last Sale

0.5900
+0.0101
+1.74%
盘前: 0.5999 +0.0099 +1.68% 08:42 09/16 EDT
开盘
0.6000
昨收
0.5799
最高
0.6300
最低
0.5800
成交量
43.67万
成交额
--
52周最高
1.260
52周最低
0.4896
市值
4,065.50万
市盈率(TTM)
7.04
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BLPH 新闻

  • Bellerophon Reports Received Orphan Drug Designation For Nitric Oxide In Treatment Of Idiopathic Pulmonary Fibrosis
  • Benzinga.17分钟前
  • 25 Healthcare Stocks Moving In Wednesday's Pre-Market Session
  • Benzinga.5天前
  • Bellerophon Therapeutics Granted FDA Orphan Drug Designation For Inhaled Nitric Oxide
  • Benzinga.5天前
  • Bellerophon to Present at the H.C. Wainwright 21st Annual Global Investment Conference
  • GlobeNewswire.09/04 12:30

更多

所属板块

生物技术和医学研究
+0.20%
制药与医学研究
-0.38%

热门股票

名称
价格
涨跌幅

BLPH 简况

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company's second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company's BCM is in PRESERVATION I clinical trial.
展开

Webull提供Bellerophon Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。